{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=118",
    "query": {
      "intervention": "Control Capsules",
      "page": 118
    },
    "page_size": 10
  },
  "pagination": {
    "page": 118,
    "page_size": 10,
    "total_count": 2912,
    "total_pages": 292,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=119&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=117&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T12:21:16.701Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05947383",
      "title": "Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sunstone Medical",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2023-10-23",
      "completion_date": "2027-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05947383"
    },
    {
      "nct_id": "NCT06006624",
      "title": "Exparel vs Block for ACL Reconstruction",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "ACL",
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Exparel 30 mL",
          "type": "DRUG"
        },
        {
          "name": "0.5% bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "iPACK block",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rothman Institute Orthopaedics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2023-08-21",
      "completion_date": "2024-10-30",
      "has_results": false,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06006624"
    },
    {
      "nct_id": "NCT05377242",
      "title": "Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gulf War Illness"
      ],
      "interventions": [
        {
          "name": "Curcumin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Resveratrol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Stinging Nettle",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 390,
      "start_date": "2023-05-31",
      "completion_date": "2026-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377242"
    },
    {
      "nct_id": "NCT02579096",
      "title": "CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gout",
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "allopurinol capsule, 100-800 mg by mouth once daily",
          "type": "DRUG"
        },
        {
          "name": "febuxostat tablet 40-120 mg by mouth once daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo, vehicle control (febuxostat-shaped)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, vehicle control (allopurinol-shaped)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 950,
      "start_date": "2017-03-06",
      "completion_date": "2021-04-15",
      "has_results": true,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 23,
      "location_summary": "Loma Linda, California • San Diego, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579096"
    },
    {
      "nct_id": "NCT02009488",
      "title": "Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin, 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "25 Years to 70 Years"
      },
      "enrollment_count": 59,
      "start_date": "2014-09-08",
      "completion_date": "2017-01-03",
      "has_results": false,
      "last_update_posted_date": "2018-01-04",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 2,
      "location_summary": "San Diego, La Jolla, California • Gainesville, Florida",
      "locations": [
        {
          "city": "San Diego, La Jolla",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02009488"
    },
    {
      "nct_id": "NCT00784654",
      "title": "Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine dimesylate (LDX)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 276,
      "start_date": "2009-01-27",
      "completion_date": "2011-10-26",
      "has_results": true,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 4,
      "location_summary": "Rolling Hills Estates, California • South Miami, Florida • Overland Park, Kansas + 1 more",
      "locations": [
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784654"
    },
    {
      "nct_id": "NCT00415142",
      "title": "An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "saredutant (SR48968)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "escitalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "60 Years to 64 Years"
      },
      "enrollment_count": 393,
      "start_date": "2006-12",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2016-05-24",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00415142"
    },
    {
      "nct_id": "NCT01311869",
      "title": "Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leiomyoma"
      ],
      "interventions": [
        {
          "name": "EGCG ( Green Tea extract)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Brown rice pills",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Meharry Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 43,
      "start_date": "2010-12",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2013-10-24",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01311869"
    },
    {
      "nct_id": "NCT00649805",
      "title": "Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Verelan® PM Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-01",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00649805"
    },
    {
      "nct_id": "NCT03760003",
      "title": "Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "ABX464 100 mg",
          "type": "DRUG"
        },
        {
          "name": "ABX464 50 mg",
          "type": "DRUG"
        },
        {
          "name": "ABX464 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abivax S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 355,
      "start_date": "2019-08-13",
      "completion_date": "2021-04-16",
      "has_results": true,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-11-10T12:21:16.701Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Decatur, Georgia • Austin, Texas + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03760003"
    }
  ]
}